Cargando…
The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
CONTEXT: Adrenal insufficiency (AI) is a life-threatening condition complicating heterogeneous disorders across various disciplines, with challenging diagnosis and a notable drug-induced component. OBJECTIVE: This work aimed to describe the spectrum of drug-induced AI through adverse drug event repo...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282361/ https://www.ncbi.nlm.nih.gov/pubmed/35704533 http://dx.doi.org/10.1210/clinem/dgac359 |
_version_ | 1784747086943617024 |
---|---|
author | Raschi, Emanuel Fusaroli, Michele Massari, Francesco Mollica, Veronica Repaci, Andrea Ardizzoni, Andrea Poluzzi, Elisabetta Pagotto, Uberto Di Dalmazi, Guido |
author_facet | Raschi, Emanuel Fusaroli, Michele Massari, Francesco Mollica, Veronica Repaci, Andrea Ardizzoni, Andrea Poluzzi, Elisabetta Pagotto, Uberto Di Dalmazi, Guido |
author_sort | Raschi, Emanuel |
collection | PubMed |
description | CONTEXT: Adrenal insufficiency (AI) is a life-threatening condition complicating heterogeneous disorders across various disciplines, with challenging diagnosis and a notable drug-induced component. OBJECTIVE: This work aimed to describe the spectrum of drug-induced AI through adverse drug event reports received by the US Food and Drug Administration (FDA). METHODS: A retrospective disproportionality analysis reporting trends of drug-induced AI was conducted on the FDA Adverse Event Reporting System (FAERS) (> 15 000 000 reports since 2004). AE reports were extracted from FAERS over the past 2 decades. Interventions included cases containing any of the preferred terms in the Medical Dictionary for Regulatory Activities describing AI, and signals of disproportionate reporting for drugs recorded in 10 or more cases as primary suspect. RESULTS: We identified 8496 cases of AI: 97.5% serious, 41.1% requiring hospitalization. AI showed an exponential increase throughout the years, with 5282 (62.2%) cases in 2015 to 2020. We identified 56 compounds associated with substantial disproportionality: glucocorticoids (N = 1971), monoclonal antibodies (N = 1644, of which N = 1330 were associated with immune checkpoint inhibitors—ICIs), hormone therapy (N = 291), anti-infectives (N = 252), drugs for hypercortisolism or adrenocortical cancer diagnosis/treatment (N = 169), and protein kinase inhibitors (N = 138). Cases of AI by glucocorticoids were stable in each 5-year period (22%-27%), whereas those by monoclonal antibodies, largely ICIs, peaked from 13% in 2010 to 2015 to 33% in 2015 to 2020. CONCLUSION: We provide a comprehensive insight into the evolution of drug-induced AI, highlighting the heterogeneous spectrum of culprit drug classes and the emerging increased reporting of ICIs. We claim for the urgent identification of predictive factors for drug-induced AI, and the establishment of screening and educational protocols for patients and caregivers. |
format | Online Article Text |
id | pubmed-9282361 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-92823612022-07-18 The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System Raschi, Emanuel Fusaroli, Michele Massari, Francesco Mollica, Veronica Repaci, Andrea Ardizzoni, Andrea Poluzzi, Elisabetta Pagotto, Uberto Di Dalmazi, Guido J Clin Endocrinol Metab Online Only Articles CONTEXT: Adrenal insufficiency (AI) is a life-threatening condition complicating heterogeneous disorders across various disciplines, with challenging diagnosis and a notable drug-induced component. OBJECTIVE: This work aimed to describe the spectrum of drug-induced AI through adverse drug event reports received by the US Food and Drug Administration (FDA). METHODS: A retrospective disproportionality analysis reporting trends of drug-induced AI was conducted on the FDA Adverse Event Reporting System (FAERS) (> 15 000 000 reports since 2004). AE reports were extracted from FAERS over the past 2 decades. Interventions included cases containing any of the preferred terms in the Medical Dictionary for Regulatory Activities describing AI, and signals of disproportionate reporting for drugs recorded in 10 or more cases as primary suspect. RESULTS: We identified 8496 cases of AI: 97.5% serious, 41.1% requiring hospitalization. AI showed an exponential increase throughout the years, with 5282 (62.2%) cases in 2015 to 2020. We identified 56 compounds associated with substantial disproportionality: glucocorticoids (N = 1971), monoclonal antibodies (N = 1644, of which N = 1330 were associated with immune checkpoint inhibitors—ICIs), hormone therapy (N = 291), anti-infectives (N = 252), drugs for hypercortisolism or adrenocortical cancer diagnosis/treatment (N = 169), and protein kinase inhibitors (N = 138). Cases of AI by glucocorticoids were stable in each 5-year period (22%-27%), whereas those by monoclonal antibodies, largely ICIs, peaked from 13% in 2010 to 2015 to 33% in 2015 to 2020. CONCLUSION: We provide a comprehensive insight into the evolution of drug-induced AI, highlighting the heterogeneous spectrum of culprit drug classes and the emerging increased reporting of ICIs. We claim for the urgent identification of predictive factors for drug-induced AI, and the establishment of screening and educational protocols for patients and caregivers. Oxford University Press 2022-06-15 /pmc/articles/PMC9282361/ /pubmed/35704533 http://dx.doi.org/10.1210/clinem/dgac359 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Online Only Articles Raschi, Emanuel Fusaroli, Michele Massari, Francesco Mollica, Veronica Repaci, Andrea Ardizzoni, Andrea Poluzzi, Elisabetta Pagotto, Uberto Di Dalmazi, Guido The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System |
title | The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System |
title_full | The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System |
title_fullStr | The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System |
title_full_unstemmed | The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System |
title_short | The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System |
title_sort | changing face of drug-induced adrenal insufficiency in the food and drug administration adverse event reporting system |
topic | Online Only Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282361/ https://www.ncbi.nlm.nih.gov/pubmed/35704533 http://dx.doi.org/10.1210/clinem/dgac359 |
work_keys_str_mv | AT raschiemanuel thechangingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem AT fusarolimichele thechangingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem AT massarifrancesco thechangingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem AT mollicaveronica thechangingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem AT repaciandrea thechangingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem AT ardizzoniandrea thechangingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem AT poluzzielisabetta thechangingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem AT pagottouberto thechangingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem AT didalmaziguido thechangingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem AT raschiemanuel changingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem AT fusarolimichele changingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem AT massarifrancesco changingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem AT mollicaveronica changingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem AT repaciandrea changingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem AT ardizzoniandrea changingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem AT poluzzielisabetta changingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem AT pagottouberto changingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem AT didalmaziguido changingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem |